share_log

CRISPR Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Capital International Investors(10.2%)

SEC announcement ·  Apr 10 12:02
Summary by Moomoo AI
Capital International Investors (CII), a division of Capital Research and Management Company, has filed an amendment to its Schedule 13G with the United States Securities and Exchange Commission on March 29, 2024, indicating a significant ownership stake in CRISPR Therapeutics AG. The filing reveals that CII now beneficially owns 8,223,994 shares of CRISPR Therapeutics' common stock, which represents 10.2% of the company's total outstanding shares. This position is held solely by CII, with no shared voting or dispositive power reported. The address of CII's principal business office is located at 333 South Hope Street, 55th Floor, Los Angeles, CA 90071. The filing was certified by Jae Won Chung, Vice President and Associate Counsel of the Fund Business Management Group at Capital Research and Management Company, on April 10, 2024. The statement asserts that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of CRISPR Therapeutics.
Capital International Investors (CII), a division of Capital Research and Management Company, has filed an amendment to its Schedule 13G with the United States Securities and Exchange Commission on March 29, 2024, indicating a significant ownership stake in CRISPR Therapeutics AG. The filing reveals that CII now beneficially owns 8,223,994 shares of CRISPR Therapeutics' common stock, which represents 10.2% of the company's total outstanding shares. This position is held solely by CII, with no shared voting or dispositive power reported. The address of CII's principal business office is located at 333 South Hope Street, 55th Floor, Los Angeles, CA 90071. The filing was certified by Jae Won Chung, Vice President and Associate Counsel of the Fund Business Management Group at Capital Research and Management Company, on April 10, 2024. The statement asserts that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of CRISPR Therapeutics.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more